Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome

Table 5 Changes in baseline to endpoint measures for oxidative stress and inflammatory biomarkers in two groups

Variables		Mean ± SD Placebo(n = 28)	Mean ± SD Ellagic acid (n = 29)	P1
TAC (mg/dL)	Baseline	1.04 ± 0.03	1.03 ± 0.02	0.41
	End	1.03 ± 0.03	1.91 ± 0.07	0.032
	P2	0.358	0.028
	Mean Changes	-0.01 ± 0.00	0.88 ± 0.05	0.041
MDA (mg/dL)	Baseline	1.47 ± 0.06	1.51 ± 0.09	0.466
	End	1.45 ± 0.07	0.8 ± 0.03	0.039
	P2	0.611	0.032
	Mean Changes	-0.02 ± 0.01	-0.71 ± 0.06	0.044
TNF-α (pg/ml)	Baseline	17.01 ± 3.78	16.89 ± 4.02	0.41
	End	16.91 ± 4.04	13.5 ± 3.61	0.033
	P2	0.292	0.03
	Mean Changes	-0.1 ± 0.26	-3.39 ± 0.41	0.038
CRP(ng/ml)	Baseline	9.37 ± 3.19	9.51 ± 3.37	0.359
	End	9.23 ± 2.87	7.01 ± 2.2	0.045
	P2	0.256	0.033
	Mean Changes	-0.14 ± 0.32	-2.5 ± 1.17	0.048

Data are expressed as means ± SD. TAC Total antioxidant capacity, MDA Malondialdehyde, TNF-α Tumor necrosis factor alpha, CRP C-reactive protein
P1: Comparison of the mean of oxidative stress and inflammatory biomarkers between the two groups of Ellagic acid and placebo (Independent samples t-test)
P2: Comparison of mean of oxidative stress and inflammatory biomarkers in each group at baseline and end of study (Paired samples t-test)

ISSN: 1757-2215